Catalyst overview
Research summary
This catalyst tracks a Phase 2a update for Cholesterol Efflux Mediator™ VAR 200 in Diabetic Kidney Disease. The expected timing is based on the latest available company guidance and may change.
3/18/24- Initiate Ph2a trial in H1 2024. 6/26/25- First clinical site activated & ready for patient recruitment. 8/13/25- Preliminary data in Q4 2025, with final results in H2 2026. 11/19/25:- Company reported Q3 2025 financials and significant liquidity constraints. No new VAR 200 DKD clinical or timing updates; preliminary Ph2a data still expected in Q4 2025 with final results in H2 2026. 04/01/26:- VAR 200 DKD Ph2a program paused; prior Q4 2025/H2 2026 readouts now uncertain; timing TBA. 05/13/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.